Literature DB >> 7951679

Apolipoprotein E epsilon 4 allele in Alzheimer's disease and vascular dementia.

G B Frisoni1, L Calabresi, C Geroldi, A Bianchetti, A L D'Acquarica, S Govoni, C R Sirtori, M Trabucchi, G Franceschini.   

Abstract

The frequency of the epsilon 4 allele of the apolipoprotein E (apoE) is increased in familial and sporadic late-onset Alzheimer's disease, but its prevalence in non-Alzheimer dementias in Caucasian populations is unknown. We found that the frequency of the apoE epsilon 4 allele was 0.45 in 93 Alzheimer's disease patients, 0.46 in 23 vascular dementia patients, 0.31 in 13 dementia of the frontal type patients, and 0.18 in 51 elderly controls. The association of apoE epsilon 4 allele is not unique to Alzheimer's disease, and its importance as a risk factor for the disease should be reconsidered.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7951679     DOI: 10.1159/000106730

Source DB:  PubMed          Journal:  Dementia        ISSN: 1013-7424


  14 in total

1.  Functional brain imaging to identify affected subjects genetically at risk for Alzheimer's disease.

Authors:  S I Rapoport
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

2.  Apolipoprotein E epsilon4 allele decreases functional connectivity in Alzheimer's disease as measured by EEG coherence.

Authors:  V Jelic; P Julin; M Shigeta; A Nordberg; L Lannfelt; B Winblad; L O Wahlund
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-07       Impact factor: 10.154

3.  Age effects on atrophy rates of entorhinal cortex and hippocampus.

Authors:  An-Tao Du; Norbert Schuff; Linda L Chao; John Kornak; William J Jagust; Joel H Kramer; Bruce R Reed; Bruce L Miller; David Norman; Helena C Chui; Michael W Weiner
Journal:  Neurobiol Aging       Date:  2005-06-14       Impact factor: 4.673

4.  Clinical rationale of genetic testing in dementia.

Authors:  G B Frisoni; M Trabucchi
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-03       Impact factor: 10.154

5.  The apolipoprotein E allele epsilon 4 does not correlate with the number of senile plaques or neurofibrillary tangles in patients with Alzheimer's disease.

Authors:  M Landén; A Thorsell; A Wallin; K Blennow
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-10       Impact factor: 10.154

6.  The apolipoprotein E epsilon4 allele selectively increases the risk of frontotemporal lobar degeneration in males.

Authors:  R Srinivasan; Y Davidson; L Gibbons; A Payton; A M T Richardson; A Varma; C Julien; C Stopford; J Thompson; M A Horan; N Pendleton; S M Pickering-Brown; D Neary; J S Snowden; D M A Mann
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-02       Impact factor: 10.154

Review 7.  Cholinesterase inhibitors and vascular dementia: another string to their bow?

Authors:  Roger Bullock
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

8.  Apolipoprotein E epsilon4 genotype as a risk factor for cognitive decline and dementia: data from the Canadian Study of Health and Aging.

Authors:  Ging-Yuek R Hsiung; A Dessa Sadovnick; Howard Feldman
Journal:  CMAJ       Date:  2004-10-12       Impact factor: 8.262

9.  Evaluation of the modifying effects of unfavourable genotypes on classical clinical risk factors for ischaemic stroke.

Authors:  Z Szolnoki; F Somogyvári; A Kondacs; M Szabó; L Fodor; J Bene; B Melegh
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-12       Impact factor: 10.154

10.  The effect of APOE-epsilon4 on dementia is mediated by Alzheimer neuropathology.

Authors:  James A Mortimer; David A Snowdon; William R Markesbery
Journal:  Alzheimer Dis Assoc Disord       Date:  2009 Apr-Jun       Impact factor: 2.703

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.